Serum Analyte Profiles Associated with Crohn's Disease and Disease Location

Gabrielle Boucher, Alexandre Paradis, Geneviève Chabot-Roy, Lise Coderre, Erin E. Hillhouse, Alain Bitton, Christine Des Rosiers, Megan K. Levings, L. Philip Schumm, Mark Lazarev, Steve R. Brant, Richard Duerr, Dermot McGovern, Mark S. Silverberg, Judy Cho, Sylvie Lesage, John D. Rioux, Guy Charron, Anik Forest, Philippe GoyetteSabine Ivinson, Lawrence Joseph, Rita Kohen, Jean Lachaine, Megan Levings, Julie Thompson-Legault, Luc Vachon, Sophie Veilleux, Brian White-Guay, Manisha Bajpai, Sondra Birch, Krzysztof Borowski, Gregory Botwin, Steven R. Brant, Wei Chen, Judy H. Cho, Roberto Cordero, Justin Côté-Daigneault, Mark J. Daly, Lisa Datta, Richard H. Duerr, Melissa Filice, Philip Fleshner, Kyle Gettler, Mamta Giri, Philippe Goytte, Ke Hao, Talin Haritunians, Yuval Itan, Elyse Johnston, Liza Konnikova, Carol Landers, Dalin Li, Dermot P.B. McGovern, Emebet Mengesha, Miriam Merad, Vessela Miladinova, Shadi Nayeri, Siobhan Proksell, Milgrom Raquel, Klaudia Rymaszewski, Ksenija Sabic, Bruce Sands, L. Philip Schumm, Marc B. Schwartz, Claire L. Simpson, Joanne M. Stempak, Christine Stevens, Stephan R. Targan, Ramnik Xavier

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Crohn's disease (CD) can affect any segment of the digestive tract but is most often localized in the ileal, ileocolonic, and colorectal regions of the intestines. It is believed that the chronic inflammation in CD is a result of an imbalance between the epithelial barrier, the immune system, and the intestinal microbiota. The aim of the study was to identify circulating markers associated with CD and/or disease location in CD patients. Methods: We tested 49 cytokines, chemokines, and growth factors in serum samples from 300 patients with CD and 300 controls. After quality control, analyte levels were tested for association with CD and disease location. Results: We identified 13 analytes that were higher in CD patients relative to healthy controls and that remained significant after conservative Bonferroni correction (P < 0.0015). In particular, CXCL9, CXCL1, and interleukin IL-6 had the greatest effect and were highly significant (P < 5 × 10-7). We also identified 9 analytes that were associated with disease location, with VEGF, IL-12p70, and IL-6 being elevated in patients with colorectal disease (P < 3 × 10-4). Conclusions: Multiple serum analytes are elevated in CD. These implicate the involvement of multiple cell types from the immune, epithelial, and endothelial systems, suggesting that circulating analytes reflect the inflammatory processes that are ongoing within the gut. Moreover, the identification of distinct profiles according to disease location supports the existence of a biological difference between ileal and colonic CD, consistent with previous genetic and clinical observations.

Original languageEnglish (US)
Pages (from-to)9-20
Number of pages12
JournalInflammatory bowel diseases
Issue number1
StatePublished - Jan 1 2022

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Gastroenterology


  • Crohn's disease
  • disease location
  • serum biomarkers


Dive into the research topics of 'Serum Analyte Profiles Associated with Crohn's Disease and Disease Location'. Together they form a unique fingerprint.

Cite this